These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 35173495)

  • 1. Precise Community-Based Public Health Management: Crucial Experience Responding to COVID-19 in Wuhan, China.
    Ran L; Tan X; Zhang Y
    Risk Manag Healthc Policy; 2022; 15():171-178. PubMed ID: 35173495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. China's Public Health Policies in Response to COVID-19: From an "Authoritarian" Perspective.
    Gao J; Zhang P
    Front Public Health; 2021; 9():756677. PubMed ID: 34976920
    [No Abstract]   [Full Text] [Related]  

  • 3. Study on the Experience of Public Health System Construction in China's COVID-19 Prevention.
    Zhang P
    Front Public Health; 2021; 9():610824. PubMed ID: 33981659
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of China's Hubei control strategy for COVID-19 epidemic: an observational study.
    Liu Y; Zheng F; Du Z; Li J; Gu J; Jiang M; Yoneoka D; Gilmour S; Hao Y
    BMC Infect Dis; 2021 Aug; 21(1):820. PubMed ID: 34399697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic Use in China's Public Healthcare Institutions During the COVID-19 Pandemic: An Analysis of Nationwide Procurement Data, 2018-2020.
    Yang Y; Geng X; Liu X; Wen X; Wu R; Cui D; Mao Z
    Front Pharmacol; 2022; 13():813213. PubMed ID: 35237164
    [No Abstract]   [Full Text] [Related]  

  • 6. Management of haemophilia patients in the COVID-19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China.
    Zhang A; Liu W; Poon MC; Liu A; Luo X; Chen L; Hu Q; Yang R
    Haemophilia; 2020 Nov; 26(6):1031-1037. PubMed ID: 32892465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-Based Framework and Implementation of China's Strategy in Combating COVID-19.
    Zhao D; Lin H; Zhang Z
    Risk Manag Healthc Policy; 2020; 13():1989-1998. PubMed ID: 33116979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public Health Crises In Comparison: China's Epidemic Response Policies From SARS To COVID-19.
    Li M
    Glob Public Health; 2021; 16(8-9):1223-1236. PubMed ID: 33891518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of China's public health system response to COVID-19.
    Zhang P; Gao J
    J Glob Health; 2021 Jan; 11():05004. PubMed ID: 33643637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. China's practice to prevent and control COVID-19 in the context of large population movement.
    Xu TL; Ao MY; Zhou X; Zhu WF; Nie HY; Fang JH; Sun X; Zheng B; Chen XF
    Infect Dis Poverty; 2020 Aug; 9(1):115. PubMed ID: 32814591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective.
    Zheng SQ; Yang L; Zhou PX; Li HB; Liu F; Zhao RS
    Res Social Adm Pharm; 2021 Jan; 17(1):1819-1824. PubMed ID: 32249102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spatial transmission of SARS-CoV-2 in China under the prevention and control measures at the early outbreak.
    Liu J; Zhou Y; Ye C; Zhang G; Zhang F; Song C
    Arch Public Health; 2021 Jan; 79(1):8. PubMed ID: 33441168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Policy disparities in response to the first wave of COVID-19 between China and Germany.
    Zhang Y; Shi L; Chen H; Wang X; Sun G
    Int J Equity Health; 2021 Mar; 20(1):86. PubMed ID: 33766049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development, Status Quo, and Challenges to China's Health Informatization During COVID-19: Evaluation and Recommendations.
    Huang M; Wang J; Nicholas S; Maitland E; Guo Z
    J Med Internet Res; 2021 Jun; 23(6):e27345. PubMed ID: 34061761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding public health in China: an empirical analysis of healthcare inputs and outputs.
    Deng F; Lv JH; Wang HL; Gao JM; Zhou ZL
    Public Health; 2017 Jan; 142():73-84. PubMed ID: 28057203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming COVID-19 in China despite shortcomings of the public health system: what can we learn?
    Wang MM; Fleßa S
    Health Econ Rev; 2021 Jul; 11(1):25. PubMed ID: 34228254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responding to COVID-19: Community volunteerism and coproduction in China.
    Miao Q; Schwarz S; Schwarz G
    World Dev; 2021 Jan; 137():105128. PubMed ID: 32834397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical Insurance Information Systems in China: Mixed Methods Study.
    Li Y; Lu C; Liu Y
    JMIR Med Inform; 2020 Sep; 8(9):e18780. PubMed ID: 32673209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparative Retrospective Study of COVID-19 Responses in Four Representative Asian Countries.
    Wang X; Shi L; Zhang Y; Chen H; Jiao J; Yang M; Sun G
    Risk Manag Healthc Policy; 2022; 15():13-25. PubMed ID: 35046739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.